Top 5 Companies Providing Non Viral Drug Delivery Systems

Published: January 2026

Targeting the delivery of a pharmacological substance to its intended physiological site of action ensures that adequate concentration of the therapeutic is made available to elicit the desired clinical benefit and limit off-target / systemic toxicity. Advances in cell biology and molecular probing techniques have revealed the presence of several potential therapeutic targets for a number of difficult-to-treat diseases, localized within the confines of the cell membrane. Therefore, efficient methods of facilitating targeted drug delivery to various sub-cellular compartments is a prominent need within the modern biopharmaceutical industry.

There exist various advanced non-viral approaches for the delivery of the drug payload, these include liposomes, nanoparticles, PEGs, cell penetrating peptides, Cry protein crystals, DNA-based delivery platform and protein-based delivery platform. CPPs have been demonstrated to facilitate the delivery of biologics (such as proteins and oligonucleotides) and small molecule drugs. The carrier molecules themselves may be protein-derived, chimeric and / or synthetic.

Although several unique variants of CPPs have been identified, till date, only a few CPP-linked drugs have entered clinical trials. One of the prominent limitations of CPPs is that, at times, conjugates have been observed to remain trapped within endosomes and hence, unable to deliver their cargo into the cytoplasm. It is worth mentioning that, in recent years, many preclinical studies have reported success in the delivery of fluorophore-labeled CPPs or CPP-cargo fusions into specific target cells.

Despite the challenges associated with delivery of biotherapeutics, such interventions are in high demand, primarily owing to the improved safety and efficacy offered by them, along with low side effect profiles. Recent advances in this domain have led to the development of intracellular biologics that target disease-relevant intracellular compartments, which were previously considered inaccessible.

It is worth noting that nanoparticle drug delivery systems can also enhance the drug development process by using biomolecule-based drug delivery systems. Hence, it is anticipated that, along with the introduction of such innovative technologies that can help in driving the future growth of this industry, the rate of development and use of non-viral drug delivery is likely to increase in the coming future.

Roots Analysis has conducted an exhaustive study on Non-Viral Drug Delivery Systems Market featuring the current market landscape and future opportunity for the companies engaged in the domain, over a span of next 10 years.

Top Five Leading Non Viral Drug Delivery Systems Providers

Arcturus Therapeutics
Bio-Path Holdings
CureVac
etherna
Matinas Pharma

The figure below highlights the top companies providing non viral drug delivery systems:

Top 5 Players to Watch Non Viral Drug Delivery Systems Market

Interested in exploring all ~135 players offering non viral drug delivery systems , along with their recent initiatives?

Discover Below the Details on Top 5 Companies providing Non Viral Drug Delivery Systems

Let us dive deep into the details of the top 5 companies providing non viral drug delivery systems. It is essential to note that the selection of top players can differ substantially according to the defined criteria.

1. Arcturus Therapeutics

Company Overview

Arcturus Therapeutics is a US-based company that specializes in the development of mRNA therapeutics, using its proprietary drug delivery platforms (Lipid-enabled and Unlocked Nucleomonomer Agent modified RNA (LUNAR) and STARR) for the treatment of various indications. The company claims to leverage the aforementioned technologies for the development of potential therapeutic candidates targeting various conditions, such as cystic fibrosis and ornithine transcarbamylase (OTC) deficiency. Over the past few years, the firm has entered into several collaborations with prominent industry stakeholders, such as Johnson & Johnson, Takeda Pharmaceutical and Vingroup to enable the development of novel treatment options for various infectious and rare indications.

Details on Technologies Offered

The section provides information on the various types of technologies being offered by Arcturus Therapeutics.

Parameters	Details
Technology Name	LUNAR	STARR mRNA Technology
Type of Molecule Delivered	Biologics	Biologics
Type of Biologic Delivered	DNA Protein / Peptide RNA	RNA
Type of Drug Interaction	Encapsulation	Conjugation
Type of Vehicle Used	Lipid Nanoparticle	Lipid Nanoparticle

Recent Developments

In October 2025, Arcturus Therapeutics announced the interim data of the Phase 2 trial of ARCT-032 for the treatment of cystic fibrosis.

To know more about the recent initiatives of Arcturus Therapeutics and other companies providing non viral drug delivery systems, access full report.

2. Bio-Path Holdings

Company Overview

Bio-Path Holdings is a publicly held company focused on developing novel antisense therapeutics. The company leverages its DNAbilize platform to facilitate the reduction or elimination of proteins in patients with various types of blood diseases. Notably, the platform utilizes P-ethoxy backbone modification, which protects the DNA payload from degradation by embedding it within a hydrophobic lipid bilayer. In addition, the firm is actively advancing a pipeline of potential product candidates against a wide array of disease indications, including acute myeloid leukemia (AML), obesity and solid tumors (such as ovarian, endometrial, pancreatic and lung).

Details on Technology Offered

The section provides information on the technology being offered by Bio-Path Holdings.

Parameters	Details
Technology Name	DNAbilize
Type of Molecule Delivered	Biologics Small Molecules
Type of Biologic Delivered	DNA
Type of Drug Interaction	Encapsulation
Type of Vehicle Used	Liposome

Recent Developments

In May 2025, Bio-Path Holdings announced the third preclinical milestone of BP1001-A for treatment of obesity in type 2 diabetic patients.

To know more about the recent initiatives of Bio-Path Holdings and other companies providing non viral drug delivery systems, access full report.

3. CureVac

Company Overview

CureVac is a biopharmaceutical company engaged in the development of novel therapies using its proprietary mRNA-based drug delivery platform. The company leverages the aforementioned technology for the development of vaccines, immuno-oncology and protein-based therapies to combat various diseases, including infectious diseases, oncological and rare genetic disorders. Through strategic partnerships and collaborations, the firm is accelerating the development and commercialization of its groundbreaking therapies, making significant progress towards a healthier and sustainable future.

Details on Technology Offered

The section provides information on the technology being offered by CureVac.

Key Parameters	Specifications
Parameters	Details
Technology Name	CurVac's mRNA technology
Type of Molecule Delivered	Biologics
Type of Biologic Delivered	RNA
Type of Drug Interaction	Encapsulation
Type of Vehicle Used	CVCM, LNP

Recent Developments

In June 2025, BioNTech announced the strategic transaction for acquiring CureVac, in order to strengthen its expertise in mRNA-cancer immunotherapy.

To know more about the recent initiatives of CureVac and other companies providing non viral drug delivery systems, access full report.

4. etherna

Company Overview

etherna is a Belgium-based company, which was established as a spun out from Vrije Universiteit Brussel (VUB) university. Since its inception, the company has been primarily focused on the R&D of cancer immunotherapies based on its proprietary mRNA platform and LNP platform. The company claims to be focused on the commercialization of mRNA-based immunotherapies as off-the-shelf products for the treatment of cancer and various infectious diseases. Further, the firm is utilizing its mRNA technology platform to develop immunotherapies, which are being developed in collaboration with several large players, having the required expertise in specific disease areas.

Details on Technologies Offered

The section provides information on the various types of technologies being offered by etherna.

Parameters	Details
Technology Name	LNP Platform	mRNA technology
Type of Molecule Delivered	Biologics	Biologics
Type of Biologic Delivered	DNA RNA	RNA
Type of Drug Interaction	Encapsulation	Encapsulation
Type of Vehicle Used	Lipid Nanoparticle	LNP / naked mRNA

Recent Developments

In January 2025, etherna entered into a strategic collaboration with Dropshot Therapeutics for the integration of technologies of both companies for developing RNA-based therapeutics.

To know more about the recent initiatives of etherna and other companies providing non viral drug delivery systems, access full report.

5. Matinas Biopharma

Company Overview

Matinas Biopharma is a New Jersey-based clinical stage company focused on the development of innovative pharmaceutical products. The company utilizes its lipid-crystal nanoparticle cochleates (LNC) platform to encapsulate drugs and address the existing limitations in drug delivery. The firm claims that the proprietary technology LNC platform helps in reducing toxicity, enhancing tolerability, enabling safer delivery, and improving oral bioavailability of the therapies.

Details on Technology Offered

The section provides information on the technology being offered by Matinas Biopharma.

Parameters	Details
Technology Name	LNC Platform
Type of Molecule Delivered	Biologics Small Molecule
Type of Biologic Delivered	DNA Protein / Peptide RNA
Type of Drug Interaction	Encapsulation
Type of Vehicle Used	Lipid Nanocrystal

Recent Developments

In March 2025, Matinas Biopharma announced the appointment of Keith Murphy and Edward Neugeboren to its board of directors.

To know more about the recent initiatives of Matinas Biopharma and other companies providing non viral drug delivery systems, access full report.

What About Other Non Viral Drug Delivery System Providers Around the World?

The above article features the top five non viral drug delivery system providers selected from a pool of around 135 companies that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.

Sources: